In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Follistatin-344 | Synthetic analog Vosoritide | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Synthetic analog | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 4 | 306 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 4 (4 in people) | 90 (90 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered1 more mentions it but does not test it | 16 · 12 active | |
Shared outcomes
From the regulatory data of each peptide.
The sources we use show no clinical development. They show no approval at the EMA or elsewhere (as of 13 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Follistatin-344 | Vosoritide |
|---|---|---|
| Adverse eventsEye | 44 | 6969 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Voxzogo says: “Pediatric achondroplasia with open epiphyses”
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Follistatin-344 | Vosoritide |
|---|---|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No randomized trial result 4 results from other study designs. | 87.8% At least one AE Placebo: 72.5% 52 weeksn = 812026 |
No randomized trial result
4 results from other study designs.
87.8%
At least one AE
Placebo: 72.5%
52 weeksn = 812026
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Follistatin-344 found in ClinicalTrials.gov.
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 16 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
BioMarin Pharmaceutical121 participants12 Dec 2016 to 30 Oct 2019
Achondroplasia
BioMarin Pharmaceutical160 participants20 Apr 2026 to est. Sept 2029
Achondroplasia
BioMarin Pharmaceutical140 participants20 Jun 2025 to est. Oct 2044
Hypochondroplasia